January 4, 2018 / 1:10 PM / 9 months ago

BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab

Jan 4 (Reuters) - Exelixis Inc:

* EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB

* EXELIXIS INC - AMENDMENT ADDS FOUR NEW EXPANSION COHORTS TO PHASE 1B TRIAL, WHICH WILL NOW INCLUDE PATIENTS WITH NSCLC AND CRPC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below